Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODX NYSE:MLSS NYSE:NSPR NASDAQ:NTRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$2.45-1.8%$3.81$1.26▼$46.50$9.02M2.843.24 million shs59,575 shsMLSSMilestone Scientific$0.42-2.0%$0.37$0.22▼$0.68$36.88M1.051.10 million shs105,780 shsNSPRInspireMD$0.72-0.4%$0.85$0.63▼$2.93$33.58M0.78168,824 shs54,469 shsNTRBNutriband$3.09+1.3%$3.34$2.90▼$9.21$37.56M1.9312,515 shs12,147 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics-3.11%-5.68%-34.13%+70.55%-68.93%MLSSMilestone Scientific+5.33%+25.81%+25.62%+59.62%-33.97%NSPRInspireMD+0.35%+3.90%-5.26%-46.67%-68.70%NTRBNutriband+2.35%-0.33%-10.56%-25.43%-62.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$2.45-1.8%$3.81$1.26▼$46.50$9.02M2.843.24 million shs59,575 shsMLSSMilestone Scientific$0.42-2.0%$0.37$0.22▼$0.68$36.88M1.051.10 million shs105,780 shsNSPRInspireMD$0.72-0.4%$0.85$0.63▼$2.93$33.58M0.78168,824 shs54,469 shsNTRBNutriband$3.09+1.3%$3.34$2.90▼$9.21$37.56M1.9312,515 shs12,147 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics-3.11%-5.68%-34.13%+70.55%-68.93%MLSSMilestone Scientific+5.33%+25.81%+25.62%+59.62%-33.97%NSPRInspireMD+0.35%+3.90%-5.26%-46.67%-68.70%NTRBNutriband+2.35%-0.33%-10.56%-25.43%-62.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 2.00Hold$67.502,660.74% UpsideMLSSMilestone Scientific 3.00Buy$1.00140.38% UpsideNSPRInspireMD 3.00Buy$4.50527.62% UpsideNTRBNutriband 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest CODX, NTRB, MLSS, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/17/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026NTRBNutriband Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/5/2026NSPRInspireMD Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $3.005/4/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.00(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$620K14.55N/AN/A$9.14 per share0.27MLSSMilestone Scientific$8.90M4.13N/AN/A$0.11 per share3.78NSPRInspireMD$10.85M3.10N/AN/A$1.83 per share0.39NTRBNutriband$1.80M20.84N/AN/A$0.55 per share5.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$46.90M-$15.77N/AN/AN/A-6,760.63%-164.92%-141.15%8/14/2026 (Estimated)MLSSMilestone Scientific-$6.93M-$0.05N/AN/AN/A-52.01%-60.26%-40.23%N/ANSPRInspireMD-$19.92M-$0.73N/AN/AN/A-413.96%-69.42%-57.68%N/ANTRBNutriband-$8.23M-$2.58N/AN/AN/A-448.25%-112.64%-97.86%N/ALatest CODX, NTRB, MLSS, and NSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026Q1 2027NTRBNutribandN/A-$0.10N/A-$0.10N/A$0.43 million5/14/2026Q1 2026CODXCo-Diagnostics-$3.75-$4.06-$0.31-$4.06$0.13 million$0.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A2.282.09MLSSMilestone ScientificN/A2.851.86NSPRInspireMDN/A6.396.05NTRBNutribandN/A5.265.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%MLSSMilestone Scientific5.79%NSPRInspireMD44.78%NTRBNutriband19.70%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics5.40%MLSSMilestone Scientific9.22%NSPRInspireMD34.06%NTRBNutriband52.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics1003.69 million3.49 millionOptionableMLSSMilestone Scientific3088.45 million58.61 millionOptionableNSPRInspireMD5046.84 million18.33 millionOptionableNTRBNutriband1012.16 million5.81 millionNot OptionableCODX, NTRB, MLSS, and NSPR HeadlinesRecent News About These CompaniesNutriband shareholders approve proposals and expand board leadershipJune 23, 2026 | theglobeandmail.comNutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM ConferenceMay 15, 2026 | globenewswire.comNutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel PodcastApril 22, 2026 | globenewswire.comNutriband Advances Lead Abuse-Deterrent Fentanyl Patch BrandingApril 7, 2026 | tipranks.comNutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl PatchMarch 30, 2026 | globenewswire.comNutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa RicaMarch 18, 2026 | finance.yahoo.comNutriband Wins Costa Rica OK for ProductMarch 18, 2026 | baystreet.caNutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa RicaFebruary 17, 2026 | globenewswire.comNutriband Cancels Planned Sale of Pocono PharmaceuticalsFebruary 14, 2026 | theglobeandmail.comNutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion PointsJanuary 30, 2026 | globenewswire.comThe past five years for Nutriband (NASDAQ:NTRB) investors has not been profitableJanuary 29, 2026 | finance.yahoo.comNutriband says ‘committed’ to shareholder value as ‘number one focus’January 1, 2026 | finance.yahoo.comNutriband Inc. CEO Shares 2025 Achievements and 2026 Outlook in Letter to ShareholdersDecember 31, 2025 | quiverquant.comQNutriband CEO Publishes Letter to ShareholdersDecember 31, 2025 | globenewswire.comNutriband Divests Pocono Stake to Fund AVERSA FentanylDecember 30, 2025 | tipranks.comWhat’s driving Nutriband shares higher today?December 29, 2025 | msn.comNutriband stock soars on sale of Pocono Pharmaceutical stakeDecember 29, 2025 | za.investing.comNutriband Inc. Sells 90% Stake in Pocono Pharmaceutical to Earthvision Bio for $5 MillionDecember 29, 2025 | quiverquant.comQNutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision BioDecember 29, 2025 | globenewswire.comNutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic ExplorationDecember 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCODX, NTRB, MLSS, and NSPR Company DescriptionsCo-Diagnostics NASDAQ:CODX$2.44 -0.05 (-1.81%) As of 02:39 PM Eastern This is a fair market value price provided by Massive. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Milestone Scientific NYSE:MLSS$0.42 -0.01 (-2.03%) As of 02:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.InspireMD NYSE:NSPR$0.72 0.00 (-0.42%) As of 02:33 PM Eastern This is a fair market value price provided by Massive. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Nutriband NASDAQ:NTRB$3.09 +0.04 (+1.31%) As of 02:41 PM Eastern This is a fair market value price provided by Massive. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Why Conagra’s Dividend Cut Could Be the Best Thing for Investors Which Storage Stock Is Best Positioned to Win the AI Memory War? Cintas Keeps Beating Expectations—And the Story Isn’t Over Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
